B · Normal
[Hailier: Some products of the subsidiary Qingdao Hengning Biological Phase II project have entered the trial production stage] On November 17, Hailier (603639.SH) announced that the company's wholly-owned subsidiary Qingdao Hengning Biological's annual output of 6,000 tons of triflufenac project and the annual output of 3,000 tons of bifenzofen project have completed the main construction of the project and equipment installation and commissioning. The trial production plan has been reviewed and approved by experts and filed, and has officially entered the trial production stage. The commissioning of the above-mentioned projects will help enrich the company's original drug product varieties and enhance core competitiveness. However, it will take time to fully reach production and generate economic benefits, and there are risks such as changes in market demand.
Comments